Profit before tax (PBT) jumped 8.7% YoY to Rs 1,619.46 crore during the quarter. EBITDA stood at Rs 3,930 crore in Q1 FY26, registering a growth of 17%, compared with Rs 3,350 crore in Q1 FY25.

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Ingersoll Rand Inc. IR reported second-quarter 2025 adjusted earnings of 80 cents per share, which matched the Zacks Consensus Estimate. The bottom line decreased 3.6% year over year. Total revenues ...

EUPD Research says the growth of the C&I segment in Europe's energy storage market is driving new investment opportunities. The Bonn-based research group has explored what this growth means for both ...

McMahan is in need of a kidney transplant, per a video posted to the Vanderbilt men’s basketball `X’ account, and McMahan is ...

Segmental dynamics are measured in pure polyisobutylene (PIB), pure deuterium-labeled head-to-head poly (propylene) (hhPP), and a blend containing 70% PIB/30% hhPP by mass using 13 C spin−lattice ...

Konami Group Corp reported revenue of just over JPY7.51 billion (US$50.2 million) in its gaming and systems division – ...

Fitch Ratings Inc has revised the rating outlook for Japan-based Universal Entertainment Corp to ‘negative’ from ‘stable’. The firm affirmed its ‘B’ long-term issuer default rating (IDR) and the ‘B-’ ...

As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.

Drug Eluting Stents are anticipated to lead the product category, holding 34.5% of the market revenue in 2025. Their clinical ...